CliffBio
small molecule

KYBELLA

DEOXYCHOLIC ACID

Loss of exclusivityFebruary 2032latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameKYBELLA
Active ingredientDEOXYCHOLIC ACID
Strength20MG/2ML (10MG/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalApril 2015
Marketing statusRX

Listed patents

PatentExpiresType
12161653February 2032use U-1940
10500214March 2030product
8653058March 2030product
8367649March 2030product
8101593March 2030product
8242294May 2028substance
8461140February 2028product
9949986February 2028use U-1940
9636349February 2028use U-1940
9522155February 2028product
8546367February 2028product
8883770February 2028product
7754230December 2027use U-1690
7622130December 2027use U-1690

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.